ES2546829T3 - Métodos y composiciones para la inhibición mediada por iARN de la expresión génica en mamíferos - Google Patents
Métodos y composiciones para la inhibición mediada por iARN de la expresión génica en mamíferos Download PDFInfo
- Publication number
- ES2546829T3 ES2546829T3 ES10178509.5T ES10178509T ES2546829T3 ES 2546829 T3 ES2546829 T3 ES 2546829T3 ES 10178509 T ES10178509 T ES 10178509T ES 2546829 T3 ES2546829 T3 ES 2546829T3
- Authority
- ES
- Spain
- Prior art keywords
- methods
- rna
- hrna
- sirna
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract description 18
- 239000000203 mixture Substances 0.000 title abstract description 13
- 230000014509 gene expression Effects 0.000 title abstract description 7
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 13
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 210000005229 liver cell Anatomy 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 108020004459 Small interfering RNA Proteins 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108010083644 Ribonucleases Proteins 0.000 description 7
- 102000006382 Ribonucleases Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000003161 ribonuclease inhibitor Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012268 protein inhibitor Substances 0.000 description 3
- 229940121649 protein inhibitor Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30741101P | 2001-07-23 | 2001-07-23 | |
| US307411P | 2001-07-23 | ||
| US36066402P | 2002-02-27 | 2002-02-27 | |
| US360664P | 2002-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2546829T3 true ES2546829T3 (es) | 2015-09-29 |
Family
ID=26975733
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10178509.5T Expired - Lifetime ES2546829T3 (es) | 2001-07-23 | 2002-07-19 | Métodos y composiciones para la inhibición mediada por iARN de la expresión génica en mamíferos |
| ES02761123T Expired - Lifetime ES2386775T3 (es) | 2001-07-23 | 2002-07-19 | Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02761123T Expired - Lifetime ES2386775T3 (es) | 2001-07-23 | 2002-07-19 | Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20030153519A1 (OSRAM) |
| EP (2) | EP2280070B1 (OSRAM) |
| JP (4) | JP2005508306A (OSRAM) |
| AT (1) | ATE556720T1 (OSRAM) |
| CA (2) | CA2936534C (OSRAM) |
| DK (2) | DK2280070T3 (OSRAM) |
| ES (2) | ES2546829T3 (OSRAM) |
| PT (1) | PT2280070E (OSRAM) |
| WO (1) | WO2003010180A1 (OSRAM) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030143204A1 (en) * | 2001-07-27 | 2003-07-31 | Lewis David L. | Inhibition of RNA function by delivery of inhibitors to animal cells |
| US20050222075A1 (en) * | 1998-09-14 | 2005-10-06 | Hans Herweijer | Process for delivering nucleic acids to cardiac tissue |
| IL145778A0 (en) * | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
| CA2403397A1 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
| ATE556720T1 (de) | 2001-07-23 | 2012-05-15 | Univ Leland Stanford Junior | Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren |
| US10590418B2 (en) * | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| US7101995B2 (en) * | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| ATE356223T1 (de) | 2001-09-25 | 2007-03-15 | Japan President Univ Tokyo | Gen und protein mit bezug zu hepatozellulärem karzinom |
| EP2455467B1 (en) | 2002-02-01 | 2016-10-05 | Life Technologies Corporation | Double-stranded oligonucleotides |
| EP1572902B1 (en) | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| EP1495120B1 (en) * | 2002-04-18 | 2012-10-10 | Acuity Pharmaceuticals, Inc | Means and methods for the specific modulation of target genes in the eye |
| US20030228691A1 (en) * | 2002-05-17 | 2003-12-11 | Lewis David L. | Processes for inhibiting gene expression using polynucleotides |
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| EP1532248B1 (en) * | 2002-07-26 | 2009-04-01 | Novartis Vaccines and Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
| US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| EP2112229A3 (en) | 2002-11-25 | 2009-12-02 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| US7781415B2 (en) * | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| CN1780912B (zh) * | 2003-02-28 | 2011-06-15 | 肿瘤疗法科学股份有限公司 | 抑制细胞生长的组合物和方法 |
| ES2439580T5 (en) * | 2003-02-28 | 2025-01-23 | Univ Johns Hopkins | T cell regulation |
| US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| NZ574973A (en) * | 2003-06-06 | 2010-10-29 | Senesco Technologies Inc | Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics |
| US20050060771A1 (en) * | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
| TWI350373B (en) | 2004-01-23 | 2011-10-11 | Oncotherapy Science Inc | Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators |
| EP1737956A2 (en) * | 2004-03-01 | 2007-01-03 | Massachusetts Institute of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
| US20050233994A1 (en) * | 2004-04-16 | 2005-10-20 | Ajamete Kaykas | Methods and vectors for expressing siRNA |
| WO2005118640A2 (en) * | 2004-04-20 | 2005-12-15 | University Of Utah Research Foundation | A h+-gated ion channel |
| JP4595939B2 (ja) * | 2004-06-22 | 2010-12-08 | 株式会社ニコン | 質感を強調する画像処理装置、画像処理プログラム、電子カメラ、および画像処理方法 |
| US20060063208A1 (en) | 2004-08-02 | 2006-03-23 | Woolf Clifford J | DRG11-responsive (DRAGON) gene and uses thereof |
| EP1778841A2 (en) * | 2004-08-11 | 2007-05-02 | Receptor Biologix, Inc. | Gastrin-specific interfering rna |
| JP2008512500A (ja) | 2004-09-10 | 2008-04-24 | ソマジェニックス インコーポレーティッド | ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法 |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| EP1796732B1 (en) * | 2004-10-01 | 2013-10-30 | Novartis Vaccines and Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| AU2005311684A1 (en) | 2004-12-02 | 2006-06-08 | University Of Massachusetts | Glucose-transport related genes, polypeptides, and methods of use thereof |
| US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
| BRPI0519690A2 (pt) * | 2004-12-30 | 2009-03-03 | Todd M Hauser | composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos |
| ES2386549T3 (es) * | 2005-01-28 | 2012-08-22 | Kyowa Hakko Kirin Co., Ltd. | Composición para inhibir la expresión de un gen diana |
| CN101189346A (zh) | 2005-02-28 | 2008-05-28 | 肿瘤疗法科学股份有限公司 | 乳腺癌相关基因znfn3a1 |
| EP1714970A1 (en) * | 2005-04-22 | 2006-10-25 | Universität des Saarlandes | Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |
| TW200741009A (en) | 2005-07-01 | 2007-11-01 | Oncotherapy Science Inc | Methods of modulating SMYD3 for treatment of cancer |
| US7919583B2 (en) * | 2005-08-08 | 2011-04-05 | Discovery Genomics, Inc. | Integration-site directed vector systems |
| US7723314B1 (en) | 2005-10-28 | 2010-05-25 | Transderm, Inc. | Methods and compositions for treating pachyonychia congenita |
| EP1970078A4 (en) | 2006-01-11 | 2010-11-17 | Kyowa Hakko Kirin Co Ltd | COMPOSITION INHIBITING THE EXPRESSION OF A TARGET GENE OF THE OCULAR GLOBE AND REMEDY FOR OCULAR GLOBE DISEASE |
| US9150882B2 (en) | 2006-01-31 | 2015-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
| EP1991008A4 (en) * | 2006-02-27 | 2012-04-18 | Nikon Corp | IMAGE PROCESSING DEVICE FOR CORRECTING MASSIVE IMAGE PERCEPTION, IMAGE PROCESSING PROGRAM AND METHOD, AND ELECTRONIC CAMERA |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| US8153369B2 (en) | 2006-06-05 | 2012-04-10 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
| ES2390499T3 (es) * | 2006-06-12 | 2012-11-13 | Opko Pharmaceuticals, Llc | Composiciones y métodos para la inhibición de la angiogénesis por sirna |
| US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| WO2008106785A1 (en) | 2007-03-05 | 2008-09-12 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
| WO2008152816A1 (en) | 2007-06-14 | 2008-12-18 | Oncotherapy Science, Inc. | Methods of identifying agents that modulate methylation of vegfr1 by smyd3 |
| EP2170395A1 (en) * | 2007-07-02 | 2010-04-07 | Wyeth LLC | Modulators of axl for use in treating bone disorders |
| WO2010008562A2 (en) | 2008-07-16 | 2010-01-21 | Recombinetics | Methods and materials for producing transgenic animals |
| KR101630888B1 (ko) | 2008-08-01 | 2016-06-15 | 교와 핫꼬 기린 가부시키가이샤 | 표적 유전자의 발현을 억제하는 조성물 |
| MX2011005851A (es) | 2008-12-04 | 2011-07-29 | Opko Opthalmics Llc | Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas. |
| ES2804764T3 (es) | 2009-06-01 | 2021-02-09 | Halo Bio Rnai Therapeutics Inc | Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos |
| US8871730B2 (en) | 2009-07-13 | 2014-10-28 | Somagenics Inc. | Chemical modification of short small hairpin RNAs for inhibition of gene expression |
| EP2666856A4 (en) | 2011-01-19 | 2015-01-14 | Kyowa Hakko Kirin Co Ltd | COMPOSITION TO INHIBIT TARGET EXPRESSION |
| CA2834788C (en) | 2011-05-05 | 2020-11-17 | Coordinated Program Development, Llc | Cochleate compositions and methods of making and using same |
| EP2873732A4 (en) | 2012-07-16 | 2016-03-23 | Kyowa Hakko Kirin Co Ltd | PHARMACEUTICAL RNAI COMPOSITION WITH SUPPRESSION OF KRAS GENE EXPRESSION |
| US9655977B2 (en) * | 2012-08-31 | 2017-05-23 | The General Hospital Corporation | Biotin complexes for treatment and diagnosis of alzheimer's disease |
| CN104342453A (zh) | 2013-08-06 | 2015-02-11 | 深圳先进技术研究院 | 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
| US9545417B2 (en) | 2014-05-01 | 2017-01-17 | The Johns Hopkins University | Methods of inhibiting cancer stem cells with HMGA1 inhibitors |
| CN106794194A (zh) | 2014-06-30 | 2017-05-31 | 中央研究院 | 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂 |
| WO2016022947A1 (en) | 2014-08-07 | 2016-02-11 | The Johns Hopkins University | Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases |
| WO2016025629A1 (en) | 2014-08-12 | 2016-02-18 | The Regents Of The University Of California | Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues |
| EP3188746B1 (en) | 2014-09-05 | 2024-06-19 | The Johns Hopkins University | Targeting capn9 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies |
| NZ738184A (en) | 2015-05-18 | 2019-09-27 | Univ California | Methods and compositions for treating aging-associated impairments |
| CA2995995A1 (en) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
| WO2018009417A1 (en) | 2016-07-05 | 2018-01-11 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| JP2020500207A (ja) | 2016-09-28 | 2020-01-09 | ブレード・セラピューティクス・インコーポレイテッド | カルパインモジュレーター及びそれらの治療上の使用 |
| US12031161B2 (en) | 2020-10-09 | 2024-07-09 | University Of Massachusetts | Targeting Nrip1 to alleviate metabolic disease |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5610050A (en) * | 1990-04-20 | 1997-03-11 | The General Hospital Corporation | Methods of preventing viral replication |
| US6344321B1 (en) | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| CA2038839A1 (en) * | 1991-03-22 | 1992-09-23 | Jiang J. Liu | Method for detection of viral rna |
| ES2040615B1 (es) * | 1991-05-27 | 1994-05-16 | Nebrda Fernando Javi Bartolome | Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis. |
| US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| JP3615545B2 (ja) * | 1993-02-01 | 2005-02-02 | キアゲン・エヌ・ブイ | 第四級アンモニウム塩界面活性剤及びそのｒｎａの単離剤 |
| US5985847A (en) | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
| US5712384A (en) * | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| EP0759979A4 (en) * | 1994-05-10 | 1999-10-20 | Gen Hospital Corp | THE ANTISENSE INHIBITION OF HEPATITIS C VIRUS |
| US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
| US5922687A (en) * | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| US5981279A (en) * | 1995-11-09 | 1999-11-09 | Allegheny University Of The Health Sciences | Compositions and methods to regulate calmodulin gene expression, and uses thereof for influencing cell growth and differentiation |
| JP4033502B2 (ja) | 1996-02-08 | 2008-01-16 | アンジェスＭｇ株式会社 | リボザイム、リポソーム製剤及びその用途 |
| WO1997036005A1 (en) * | 1996-03-26 | 1997-10-02 | Lynx Therapeutics, Inc. | Oligonucleotide treatments and compositions for human melanoma |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| WO1998044953A1 (en) | 1997-04-04 | 1998-10-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| US5948902A (en) | 1997-11-20 | 1999-09-07 | South Alabama Medical Science Foundation | Antisense oligonucleotides to human serine/threonine protein phosphatase genes |
| US5957978A (en) | 1997-12-22 | 1999-09-28 | Hansa Medical Products, Inc. | Valved fenestrated tracheotomy tube |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| NZ506648A (en) | 1998-03-20 | 2003-08-29 | Benitec Australia Ltd | Control of gene expression through introduction of synthetic tandem repeats to reduce translation of mRNA |
| AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL145778A0 (en) * | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| GB9925459D0 (en) * | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
| ES2269199T3 (es) | 1999-11-05 | 2007-04-01 | Mirus Bio Corporation | Suministro intravascular de acido nucleico. |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| DE10100586C1 (de) * | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| CA2403397A1 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
| BR0109269A (pt) | 2000-03-17 | 2002-12-17 | Benitec Australia Ltd | Construto genético e seu uso, célula de animal vertebrado, métodos de alteração do fenótipo de uma célula de animal vertebrado e de terapia genética em animal vertebrado, animal e animal murino geneticamente modificados |
| DK2796553T3 (da) | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| US20020132788A1 (en) * | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| DE10100588A1 (de) | 2001-01-09 | 2002-07-18 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Zielgens |
| EP1390472A4 (en) * | 2001-05-29 | 2004-11-17 | Sirna Therapeutics Inc | NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS |
| US7000102B2 (en) | 2001-06-29 | 2006-02-14 | Intel Corporation | Platform and method for supporting hibernate operations |
| EP1412371B1 (en) | 2001-07-12 | 2016-02-24 | University of Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| ATE556720T1 (de) | 2001-07-23 | 2012-05-15 | Univ Leland Stanford Junior | Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren |
| JP2005517427A (ja) | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | 短干渉核酸（ｓｉＮＡ）を用いるＣ型肝炎ウイルス（ＨＣＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
-
2002
- 2002-07-19 AT AT02761123T patent/ATE556720T1/de active
- 2002-07-19 EP EP10178509.5A patent/EP2280070B1/en not_active Expired - Lifetime
- 2002-07-19 DK DK10178509.5T patent/DK2280070T3/en active
- 2002-07-19 US US10/200,002 patent/US20030153519A1/en not_active Abandoned
- 2002-07-19 JP JP2003515539A patent/JP2005508306A/ja not_active Withdrawn
- 2002-07-19 PT PT101785095T patent/PT2280070E/pt unknown
- 2002-07-19 ES ES10178509.5T patent/ES2546829T3/es not_active Expired - Lifetime
- 2002-07-19 EP EP02761123A patent/EP1409506B1/en not_active Expired - Lifetime
- 2002-07-19 DK DK02761123.5T patent/DK1409506T3/da active
- 2002-07-19 WO PCT/US2002/022869 patent/WO2003010180A1/en not_active Ceased
- 2002-07-19 CA CA2936534A patent/CA2936534C/en not_active Expired - Lifetime
- 2002-07-19 CA CA2454183A patent/CA2454183C/en not_active Expired - Lifetime
- 2002-07-19 ES ES02761123T patent/ES2386775T3/es not_active Expired - Lifetime
-
2010
- 2010-11-08 JP JP2010249697A patent/JP6055164B2/ja not_active Expired - Lifetime
-
2013
- 2013-07-12 US US13/941,262 patent/US10517887B2/en not_active Expired - Fee Related
-
2014
- 2014-09-16 JP JP2014187281A patent/JP2015044809A/ja active Pending
-
2016
- 2016-08-17 JP JP2016159918A patent/JP6247355B2/ja not_active Expired - Lifetime
-
2019
- 2019-12-20 US US16/723,744 patent/US20200246370A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2454183A1 (en) | 2003-02-06 |
| DK2280070T3 (en) | 2015-08-24 |
| HK1065562A1 (en) | 2005-02-25 |
| EP2280070A1 (en) | 2011-02-02 |
| EP1409506A1 (en) | 2004-04-21 |
| DK1409506T3 (da) | 2012-08-06 |
| WO2003010180A1 (en) | 2003-02-06 |
| US20030153519A1 (en) | 2003-08-14 |
| ATE556720T1 (de) | 2012-05-15 |
| PT2280070E (pt) | 2015-10-29 |
| EP1409506A4 (en) | 2004-11-17 |
| JP2005508306A (ja) | 2005-03-31 |
| ES2386775T3 (es) | 2012-08-30 |
| CA2454183C (en) | 2016-09-06 |
| CA2936534A1 (en) | 2003-02-06 |
| US20130312126A1 (en) | 2013-11-21 |
| EP2280070B1 (en) | 2015-05-20 |
| JP2011093906A (ja) | 2011-05-12 |
| CA2936534C (en) | 2021-01-26 |
| JP2017008084A (ja) | 2017-01-12 |
| EP1409506B1 (en) | 2012-05-09 |
| JP2015044809A (ja) | 2015-03-12 |
| JP6055164B2 (ja) | 2016-12-27 |
| US10517887B2 (en) | 2019-12-31 |
| US20200246370A1 (en) | 2020-08-06 |
| JP6247355B2 (ja) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2546829T3 (es) | Métodos y composiciones para la inhibición mediada por iARN de la expresión génica en mamíferos | |
| JP7007304B2 (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| RU2648950C2 (ru) | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение | |
| ES2862955T5 (en) | Engineered nucleic acids and methods of use thereof | |
| EP2892617B1 (en) | Antisense polynucleotides to induce exon skipping and methods of treating dystrophies | |
| US20030124513A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV | |
| EP3030244B1 (en) | Polyconjugates for delivery of rnai triggers to tumor cells in vivo | |
| CN106999534A (zh) | 用于治疗急性辐射综合症的组合物和方法 | |
| ES2886946T3 (es) | Péptido con efecto antiviral y composición que lo contiene | |
| US20150344887A1 (en) | siRNA FOR INHIBITION OF USP15 EXPRESSION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | |
| US20200181620A1 (en) | Inhibitors of dek protein and related methods | |
| EP3463387B1 (en) | Medicament for the treatment of acute liver failure | |
| US20240352458A1 (en) | Double stranded nucleic acid compounds inhibiting zpi | |
| US20020102694A1 (en) | Nucleozymes with endonuclease activity | |
| JP5198848B2 (ja) | マクロファージ遊走阻止因子阻害剤を用いる、１型糖尿病処置 | |
| EP4067489A1 (en) | Method for reducing toxicity of antisense nucleic acids | |
| EP4166136A1 (en) | Inhalable protease inhibitors for use in the prevention and/or treatment of fibrotic autoimmune or inflammatory lung diseases | |
| KR102194594B1 (ko) | 매트릭스메탈로프로티나제-1 안티센스 올리고뉴클레오티드 | |
| CN110462042B (zh) | 抗病毒剂 | |
| JP2007015926A (ja) | Ｃ型肝炎治療剤 | |
| CN107709561A (zh) | 修饰的siRNA及含有该修饰的siRNA的药物组合物 | |
| KR101527749B1 (ko) | miR-186, miR-216b, miR-337-3p 및 miR-760 억제제를 유효성분으로 포함하는 세포 노화 예방 또는 치료용 조성물 | |
| KR20020069392A (ko) | 인간의 페록시레독신 ｉｉ 안티센스 서열 및 이의 용도 | |
| ES3023937T3 (en) | Pharmaceutical compositions for use in treating an hbv or hdv infection | |
| CN101643729B (zh) | 核酸分子nrn1sr22及其在制备抗癌药物中的应用 |